292.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace
RNAi Leader Alnylam Set for Major Presentation at Goldman Sachs Healthcare Conference - Stock Titan
Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch By Investing.com - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock outlook amid Amvuttra launch - Investing.com
Biogen partners with John Maraganore’s new RNAi startup - The Business Journals
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Alnylam supports LGBT community inside and outside the workplace - The Business Journals
3 High-Flying Stocks That Could Soar Even More - AOL.com
Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com
Alnylam Issues 2024 Corporate Responsibility Report - BioSpace
Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus
Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN
Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus
Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire
High Growth US Tech Stocks To Watch In May 2025 - simplywall.st
Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader
Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters
Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo
Alnylam shareholders approve executive compensation plan - Investing.com
Alnylam Pharma Re-elects Directors at Annual Meeting - TipRanks
12 Best Growth Stocks to Buy and Hold for the Long Term - Insider Monkey
Hypercholesterolemia Treatment Market Top Companies Study - openPR.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Target Price from Analysts - Defense World
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - simplywall.st
Alnylam to present key data on amyloidosis treatments By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance
Alnylam (ALNY) to Unveil Latest Transthyretin Amyloidosis Data a - GuruFocus
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress - marketscreener.com
Alnylam to Share Progress Across its Transthyretin Amyloidosis F - GuruFocus
Alnylam to present key data on amyloidosis treatments - Investing.com Australia
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire
Trend Tracker for (ALNY) - news.stocktradersdaily.com
‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review
RNA Therapy Market Booms Amid Advancements in mRNA and Gene - openPR.com
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga
LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN
Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com
Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):